Tricyclic Antidepressant (TCA) — Active Metabolite of Amitriptyline
Pregnancy: Avoid if possible — use sertraline in preference. Neonatal withdrawal reported.
Nortriptyline
Brand names: Allegron
Adult dose
Dose: Depression: 75–100mg daily (start 25mg TDS or 75mg OD at night); maximum 150mg daily. Neuropathic pain: 10–25mg ON initially; titrate to 50–75mg ON.
Route: Oral
Frequency: Once daily at night or in divided doses (TDS)
Max: 150mg daily (depression); 75mg ON (neuropathic pain)
Nortriptyline is the active metabolite of amitriptyline — less sedating and less anticholinergic than amitriptyline. Preferred TCA in elderly due to slightly better tolerability profile. Plasma level monitoring available and clinically useful (therapeutic range 50–150 nanograms/mL). Less weight gain than amitriptyline.
Paediatric dose
Route: Oral
Frequency: Once daily at night
Max: Individualised
BNFc: Nocturnal enuresis (7–17 years): 10–35mg ON, adjusted up to 35–70mg ON. Not licensed for depression under 18 years. Seek specialist paediatric opinion.
Dose adjustments
Renal
Use with caution — limited data; potential accumulation in severe impairment.
Hepatic
Avoid in severe hepatic impairment — reduced metabolism, accumulation risk.
Clinical pearls
- Therapeutic drug monitoring (TDM) is clinically useful for nortriptyline — target plasma level 50–150 nanograms/mL. Helps guide dose titration and assess adherence
- Preferred TCA in elderly for neuropathic pain — less sedating and anticholinergic than amitriptyline; still Beers Criteria caution but relatively better tolerated
- Overdose antidote (cardiac toxicity): IV sodium bicarbonate — same as amitriptyline
- Less sedating than amitriptyline — may be preferred when daytime sedation is problematic
Contraindications
- Recent MI
- Arrhythmias, heart block
- Mania
- Closed-angle glaucoma
- MAOIs within 14 days
- Hypersensitivity to nortriptyline or TCAs
Side effects
- Orthostatic hypotension
- Dry mouth, constipation (anticholinergic — less than amitriptyline)
- Sedation (less than amitriptyline)
- QTc prolongation
- Weight gain (less than amitriptyline)
- Urinary hesitancy
Interactions
- MAOIs — contraindicated
- CYP2D6 inhibitors (paroxetine, fluoxetine) — significantly increase nortriptyline levels; monitor plasma levels
- QT-prolonging drugs — additive
- Adrenaline — interaction as per amitriptyline
Monitoring
- Plasma level (nortriptyline TDM — target 50–150 ng/mL)
- ECG (QTc)
- Orthostatic blood pressure
- Anticholinergic symptom review
Reference: BNFc; BNF 90; NICE NG59 (Neuropathic Pain). Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF